{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","spread":"0.0","upperLimit":"70.8","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","spread":"0.0","upperLimit":"21.8","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with BOR of CR or PR based on investigator assessment according to RECIST version 1.1 for non-HGG cohorts and RANO for HGG cohort. CR was defined as disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \\<10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with recurrent or refractory solid tumors received lenvatinib 8 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily in cycle 1 (each cycle was 28 days) until the occurrence of PD, clinical benefit, development of unacceptable toxicity leading to withdrawal from the study, study discontinuation or for a maximum of 18 cycles (each cycle was 28 days) whichever occurred first.","id":"OG000","title":"Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2"},{"description":"Participants with recurrent or refractory solid tumors received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily in cycle 1 (each cycle was 28 days) until the occurrence of PD, clinical benefit, development of unacceptable toxicity leading to withdrawal from the study, study discontinuation or for a maximum of 18 cycles (each cycle was 28 days) whichever occurred first.","id":"OG001","title":"Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2"}],"paramType":"NUMBER","populationDescription":"SAS included all participants who received at least 1 dose of study drug (lenvatinib or everolimus). Here, 'overall number of participants analyzed' signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From the date of the first dose of study drug to the date of first documentation of disease progression or death, whichever occurred first (up to 16.5 months)","title":"Phase 1: Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}